08
2022-07
Kintor Pharma: Q2 2022 Business Update at a Glance
Kintor Pharma Q2 2022 Business Update at a Glance
14
2022-06
Suzhou, June 14, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that its “clinical trial cooperative research and development and overseas application demonstration of the anti-COVID-19 drug (pruxelutamide, used to be called proxalutamide)” project was selected as one of the Belt and Road Innovation Cooperation Projects and was included in the list of proposed projects for special fund supported by the Jiangsu Provincial Department of Science and Technology (Innovation Support Plan for International Science and Technology Cooperation/Hong Kong, Macao, and Taiwan Science and Technology Cooperation). Kintor Pharma and Etana, an Indonesian company, developed the project together.
15
2022-05
Kintor Pharma Included in MSCI China Index
Suzhou, May 15, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced today that the company’s stock has been included in the MSCI China Index, effective May 31, 2022.
04
2022-05
Suzhou, May 4, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in the United States of its multi-regional phase II clinical trial (NCT05178043) of ALK-1 antibody (GT90001) and Nivolumab (Opdivo) combination therapy for the treatment of advanced Hepatocellular Carcinoma (HCC) on 2 May 2022.
06
2022-04
Suzhou, April 6, 2022, Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the top-line results of the Phase III MRCT of proxalutamide in outpatients with mild to moderate COVID-19 regardless of vaccination status and risk factors.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn